Adjuvant

Disease,cancers,therapies,response,study,types,chemotherapy,tumors,factor,adjuvant therapy,epidermal growth factor receptor,health,systemic therapy,hazard ratio,survival,women,median follow-up,Adjuvant treatment,patients with stage,clinical stage,women with breast cancer,therapy in patients.

Neoadjuvant therapy,immune response,neoadjuvant chemotherapy,adjuvant chemotherapy,disease-free survival,activity,health care provider,aluminum,aluminum salts,triple-negative breast cancer,patients with breast cancer,early-stage breast cancer,endocrine therapy,radiation therapy,autoimmune disease.

Node-positive disease,complete response,chemotherapy in patients,tumor size,ratio,recurrence-free survival,aluminum hydroxide,drugs,medical advice,risk of relapse,dose reduction,immune cells,systemic treatment,Breast Cancer,invasive breast cancer,invasive cancer,metastatic breast cancer,HER2-negative breast cancer,high-risk early breast cancer,National Comprehensive Cancer Network,Non-small Cell Lung Cancer,breast cancer recurrence,contralateral breast cancer,Early-stage breast cancer treatment,THERAPY For patients,anti-HER2 therapy.

HER2-positive disease,invasive disease,disease progression,cell responses,Innate responses,primary tumor,smaller, node-negative tumors,immunity,innate immunity,protective immunity,cardiac risk factors,prognostic factor,ratio for recurrence,Immunol,adjuvant activity,activity of alum,premenopausal women,immunotherapy,database,confidence intervals,complete resection,Didierlaurent et al.,congestive heart failure,Marrack et al.,Hornung et al.,McKee et al.,Dupuis et al.,Distant recurrences,patients with hormone receptor,patients with hormone,American Joint Committee on Cancer,hormone receptor-positive breast cancer,cancer cells,HER2-directed therapy,extended therapy,standard therapy,risk for disease recurrence,triple-negative disease,adaptive responses,adjuvant core response genes,chemotherapy versus surgery,Node-negative tumors,adaptive immunity,humoral immunity,ratio for death,study sponsor,entire study population,J. Immunol,Nat Immunol,National Institutes of Health,postmenopausal women,type of eligibility criteria,arm type,neoadjuvant immunotherapy,adjuvant immunotherapy,Food and Drug Administration,U.S. Food and Drug Administration,Cochrane Database Syst,Cochrane Database Syst Rev.